Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

METACRINE, INC.

(MTCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

METACRINE, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

03/18/2021 | 05:37am EDT

Item 2.02 Results of Operations and Financial Condition.

On March 18, 2021, Metacrine, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2020. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 16, 2021, Dr. Robert Adelman informed the Board of Directors (the "Board") of Metacrine, Inc. (the "Company") of his resignation as a member of the Board and the Compensation Committee of the Board, effective as of March 17, 2021. Dr. Adelman's decision to resign was not related to any disagreement with the Company over any of its operations, policies, or practices.

On March 17, 2021, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Jeffrey Jonker to the Board, to fill the vacancy created by Dr. Adelman's resignation. Mr. Jonker was appointed as a Class I director with a term expiring at the 2021 annual meeting of stockholders at which time he will stand for reelection by the Company's stockholders. The Board determined that Mr. Jonker is independent under the listing standards of The Nasdaq Stock Market.

As a non-employee director, Mr. Jonker will receive compensation for his Board service in accordance with the Company's Non-Employee Director Compensation Policy, previously filed as Exhibit 10.5 to the Company's registration statement on Form S-1 (File No 333-248292), which policy is incorporated herein by reference. In addition, Mr. Jonker has entered into an indemnity agreement with the Company in the form previously entered into between the Company and its existing non-employee directors. Mr. Jonker is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Mr. Jonker and any other persons pursuant to which he was selected as a director. Mr. Jonker has not been appointed to any committee of the Board at this time.

On March 18, 2021, the Company issued a press release announcing Mr. Jonker's appointment. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.



        (d)   The following exhibit is furnished with this Current Report.




                Exhibit
                Number                  Description
                 99.1       Press release dated March 18, 2021.


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about METACRINE, INC.
06/17Metacrine and Its Partners to Present Data at the EASL International Liver Co..
GL
06/14METACRINE  : HC Wainwright Starts Metacrine at Buy With $15 Price Target
MT
06/02METACRINE  : Achieves Enrollment Milestone in Phase 2a Trial of Diabetes/NASH Co..
MT
06/02Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in P..
GL
05/26METACRINE, INC.  : Change in Directors or Principal Officers, Submission of Matt..
AQ
05/26Metacrine to Present at 2021 Jefferies Healthcare Conference
GL
05/19Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Dis..
GL
05/18METACRINE  : Enrolls First 60 Patients in Phase 2a Trial of MET642
MT
05/18Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analys..
GL
05/14METACRINE  : RBC Reduces Price Target on Metacrine to $22 From $25, Maintains Ou..
MT
More news